Seeking Alpha
30 Oct 2026, 09:35 UTC · 1h ago
Eli Lilly: The Bar Just Got Higher
Impact · against what's priced in
Eli Lilly's strong Q3 results and raised guidance are largely neutral catalysts as they align with existing market expectations for high GLP-1 growth. While the revenue beat is impressive, the current price already assumes a high baseline for 2026, leaving the stock sensitive to valuation multiples rather than incremental guidance raises.
- LLY+0.00
Already priced in
- The price assumes
Revenue guidance of $85–87 billion for 2026
The $5.5B raise in FY26 guidance and 39% Q3 growth simply validate the aggressive revenue targets the market has already baked into the price.
What LLY's price assumes · Sep 10
Top 1 mover · tap to explore
